author_facet Romanic, Anne M.
White, Raymond F.
Arleth, Anthony J.
Ohlstein, Eliot H.
Barone, Frank C.
Romanic, Anne M.
White, Raymond F.
Arleth, Anthony J.
Ohlstein, Eliot H.
Barone, Frank C.
author Romanic, Anne M.
White, Raymond F.
Arleth, Anthony J.
Ohlstein, Eliot H.
Barone, Frank C.
spellingShingle Romanic, Anne M.
White, Raymond F.
Arleth, Anthony J.
Ohlstein, Eliot H.
Barone, Frank C.
Stroke
Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
Advanced and Specialized Nursing
Cardiology and Cardiovascular Medicine
Neurology (clinical)
author_sort romanic, anne m.
spelling Romanic, Anne M. White, Raymond F. Arleth, Anthony J. Ohlstein, Eliot H. Barone, Frank C. 0039-2499 1524-4628 Ovid Technologies (Wolters Kluwer Health) Advanced and Specialized Nursing Cardiology and Cardiovascular Medicine Neurology (clinical) http://dx.doi.org/10.1161/01.str.29.5.1020 <jats:p><jats:italic>Background and Purpose</jats:italic>—Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade the extracellular matrix and are implicated in numerous pathological conditions including atherosclerosis, inflammation, and tumor growth and metastasis. In the brain, the endothelial cell wall, strengthened by tight junctions, defines the blood-brain barrier (BBB). The extracellular matrix molecules constitute the basement membrane underlying the vasculature and play a critical role in maintaining the integrity of the BBB. After focal stroke, there is a breakdown of the BBB with an associated increase in vascular permeability, inflammatory cell influx, and neuronal cell death. The present study was designed to investigate the effects of MMP expression after stroke.</jats:p><jats:p><jats:italic>Methods</jats:italic>—Focal stroke was produced by permanent middle cerebral artery occlusion (MCAO) in the rat, and MMP protein expression was measured by Western blot and zymogram analysis over a time course ranging from 6 hours to 30 days (n=32). Immunohistochemistry at 1 and 5 days (n=8 and 6, respectively) was also utilized to characterize the expression of several MMPs and related proteins after stroke, including their cellular source. To test the hypothesis that early increased MMP-9 expression is involved in ischemic brain injury, a neutralizing monoclonal antibody directed against MMP-9 was administered intravenously (n=7 per group) 1 hour before MCAO, and infarct size was measured 24 hours later.</jats:p><jats:p><jats:italic>Results</jats:italic>—MMP expression increased progressively over time after stroke. After 12 hours, significant (<jats:italic>P</jats:italic>&lt;0.05) MMP-9 activity was observed that reached maximum levels by 24 hours (<jats:italic>P</jats:italic>&lt;0.001), then persisted for 5 days at this level and returned to basal (zero) levels by 15 days. On the basis of morphological criteria, MMP-9 appeared to stain with endothelial cells and neutrophils identified both within and at the periphery of the infarct within 24 hours of focal ischemia. After 5 days, MMP-9 appeared to stain with macrophages present within the infarcted brain. MMP-2 activity was significantly (<jats:italic>P</jats:italic>&lt;0.001) increased by 24 hours and was maximum after 5 days following MCAO. MMP-2 appeared to stain with macrophages present within the infarcted region. Unlike MMP-9 and MMP-2, tissue inhibitor of metalloproteinase-1 was identified at comparable levels in both control and ischemic tissue after MCAO. MMP-1 and MMP-3 could not be detected in the brain after focal stroke. When an MMP-9–neutralizing monoclonal antibody was administered systemically, animals exhibited significantly reduced infarct size (ie, a 30% reduction compared with non–immune antibody controls;<jats:italic>P</jats:italic>&lt;0.05).</jats:p><jats:p><jats:italic>Conclusions</jats:italic>—These results demonstrate that early increased MMP-9 expression in endothelial cells and infiltrating neutrophils is a significant response to cerebral focal ischemia and that selective inhibition of MMP-9 activity can significantly reduce brain injury after stroke.</jats:p> Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size Stroke
doi_str_mv 10.1161/01.str.29.5.1020
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5zdHIuMjkuNS4xMDIw
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5zdHIuMjkuNS4xMDIw
institution DE-D161
DE-Zwi2
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
imprint Ovid Technologies (Wolters Kluwer Health), 1998
imprint_str_mv Ovid Technologies (Wolters Kluwer Health), 1998
issn 0039-2499
1524-4628
issn_str_mv 0039-2499
1524-4628
language English
mega_collection Ovid Technologies (Wolters Kluwer Health) (CrossRef)
match_str romanic1998matrixmetalloproteinaseexpressionincreasesaftercerebralfocalischemiainratsinhibitionofmatrixmetalloproteinase9reducesinfarctsizeinhibitionofmatrixmetalloproteinase9reducesinfarctsize
publishDateSort 1998
publisher Ovid Technologies (Wolters Kluwer Health)
recordtype ai
record_format ai
series Stroke
source_id 49
title_sub Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_unstemmed Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_full Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_fullStr Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_full_unstemmed Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_short Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_sort matrix metalloproteinase expression increases after cerebral focal ischemia in rats : inhibition of matrix metalloproteinase-9 reduces infarct size
topic Advanced and Specialized Nursing
Cardiology and Cardiovascular Medicine
Neurology (clinical)
url http://dx.doi.org/10.1161/01.str.29.5.1020
publishDate 1998
physical 1020-1030
description <jats:p><jats:italic>Background and Purpose</jats:italic>—Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade the extracellular matrix and are implicated in numerous pathological conditions including atherosclerosis, inflammation, and tumor growth and metastasis. In the brain, the endothelial cell wall, strengthened by tight junctions, defines the blood-brain barrier (BBB). The extracellular matrix molecules constitute the basement membrane underlying the vasculature and play a critical role in maintaining the integrity of the BBB. After focal stroke, there is a breakdown of the BBB with an associated increase in vascular permeability, inflammatory cell influx, and neuronal cell death. The present study was designed to investigate the effects of MMP expression after stroke.</jats:p><jats:p><jats:italic>Methods</jats:italic>—Focal stroke was produced by permanent middle cerebral artery occlusion (MCAO) in the rat, and MMP protein expression was measured by Western blot and zymogram analysis over a time course ranging from 6 hours to 30 days (n=32). Immunohistochemistry at 1 and 5 days (n=8 and 6, respectively) was also utilized to characterize the expression of several MMPs and related proteins after stroke, including their cellular source. To test the hypothesis that early increased MMP-9 expression is involved in ischemic brain injury, a neutralizing monoclonal antibody directed against MMP-9 was administered intravenously (n=7 per group) 1 hour before MCAO, and infarct size was measured 24 hours later.</jats:p><jats:p><jats:italic>Results</jats:italic>—MMP expression increased progressively over time after stroke. After 12 hours, significant (<jats:italic>P</jats:italic>&lt;0.05) MMP-9 activity was observed that reached maximum levels by 24 hours (<jats:italic>P</jats:italic>&lt;0.001), then persisted for 5 days at this level and returned to basal (zero) levels by 15 days. On the basis of morphological criteria, MMP-9 appeared to stain with endothelial cells and neutrophils identified both within and at the periphery of the infarct within 24 hours of focal ischemia. After 5 days, MMP-9 appeared to stain with macrophages present within the infarcted brain. MMP-2 activity was significantly (<jats:italic>P</jats:italic>&lt;0.001) increased by 24 hours and was maximum after 5 days following MCAO. MMP-2 appeared to stain with macrophages present within the infarcted region. Unlike MMP-9 and MMP-2, tissue inhibitor of metalloproteinase-1 was identified at comparable levels in both control and ischemic tissue after MCAO. MMP-1 and MMP-3 could not be detected in the brain after focal stroke. When an MMP-9–neutralizing monoclonal antibody was administered systemically, animals exhibited significantly reduced infarct size (ie, a 30% reduction compared with non–immune antibody controls;<jats:italic>P</jats:italic>&lt;0.05).</jats:p><jats:p><jats:italic>Conclusions</jats:italic>—These results demonstrate that early increased MMP-9 expression in endothelial cells and infiltrating neutrophils is a significant response to cerebral focal ischemia and that selective inhibition of MMP-9 activity can significantly reduce brain injury after stroke.</jats:p>
container_issue 5
container_start_page 1020
container_title Stroke
container_volume 29
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792348556427788291
geogr_code not assigned
last_indexed 2024-03-01T18:13:03.233Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Matrix+Metalloproteinase+Expression+Increases+After+Cerebral+Focal+Ischemia+in+Rats+%3A+Inhibition+of+Matrix+Metalloproteinase-9+Reduces+Infarct+Size&rft.date=1998-05-01&genre=article&issn=1524-4628&volume=29&issue=5&spage=1020&epage=1030&pages=1020-1030&jtitle=Stroke&atitle=Matrix+Metalloproteinase+Expression+Increases+After+Cerebral+Focal+Ischemia+in+Rats+%3A+Inhibition+of+Matrix+Metalloproteinase-9+Reduces+Infarct+Size&aulast=Barone&aufirst=Frank+C.&rft_id=info%3Adoi%2F10.1161%2F01.str.29.5.1020&rft.language%5B0%5D=eng
SOLR
_version_ 1792348556427788291
author Romanic, Anne M., White, Raymond F., Arleth, Anthony J., Ohlstein, Eliot H., Barone, Frank C.
author_facet Romanic, Anne M., White, Raymond F., Arleth, Anthony J., Ohlstein, Eliot H., Barone, Frank C., Romanic, Anne M., White, Raymond F., Arleth, Anthony J., Ohlstein, Eliot H., Barone, Frank C.
author_sort romanic, anne m.
container_issue 5
container_start_page 1020
container_title Stroke
container_volume 29
description <jats:p><jats:italic>Background and Purpose</jats:italic>—Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade the extracellular matrix and are implicated in numerous pathological conditions including atherosclerosis, inflammation, and tumor growth and metastasis. In the brain, the endothelial cell wall, strengthened by tight junctions, defines the blood-brain barrier (BBB). The extracellular matrix molecules constitute the basement membrane underlying the vasculature and play a critical role in maintaining the integrity of the BBB. After focal stroke, there is a breakdown of the BBB with an associated increase in vascular permeability, inflammatory cell influx, and neuronal cell death. The present study was designed to investigate the effects of MMP expression after stroke.</jats:p><jats:p><jats:italic>Methods</jats:italic>—Focal stroke was produced by permanent middle cerebral artery occlusion (MCAO) in the rat, and MMP protein expression was measured by Western blot and zymogram analysis over a time course ranging from 6 hours to 30 days (n=32). Immunohistochemistry at 1 and 5 days (n=8 and 6, respectively) was also utilized to characterize the expression of several MMPs and related proteins after stroke, including their cellular source. To test the hypothesis that early increased MMP-9 expression is involved in ischemic brain injury, a neutralizing monoclonal antibody directed against MMP-9 was administered intravenously (n=7 per group) 1 hour before MCAO, and infarct size was measured 24 hours later.</jats:p><jats:p><jats:italic>Results</jats:italic>—MMP expression increased progressively over time after stroke. After 12 hours, significant (<jats:italic>P</jats:italic>&lt;0.05) MMP-9 activity was observed that reached maximum levels by 24 hours (<jats:italic>P</jats:italic>&lt;0.001), then persisted for 5 days at this level and returned to basal (zero) levels by 15 days. On the basis of morphological criteria, MMP-9 appeared to stain with endothelial cells and neutrophils identified both within and at the periphery of the infarct within 24 hours of focal ischemia. After 5 days, MMP-9 appeared to stain with macrophages present within the infarcted brain. MMP-2 activity was significantly (<jats:italic>P</jats:italic>&lt;0.001) increased by 24 hours and was maximum after 5 days following MCAO. MMP-2 appeared to stain with macrophages present within the infarcted region. Unlike MMP-9 and MMP-2, tissue inhibitor of metalloproteinase-1 was identified at comparable levels in both control and ischemic tissue after MCAO. MMP-1 and MMP-3 could not be detected in the brain after focal stroke. When an MMP-9–neutralizing monoclonal antibody was administered systemically, animals exhibited significantly reduced infarct size (ie, a 30% reduction compared with non–immune antibody controls;<jats:italic>P</jats:italic>&lt;0.05).</jats:p><jats:p><jats:italic>Conclusions</jats:italic>—These results demonstrate that early increased MMP-9 expression in endothelial cells and infiltrating neutrophils is a significant response to cerebral focal ischemia and that selective inhibition of MMP-9 activity can significantly reduce brain injury after stroke.</jats:p>
doi_str_mv 10.1161/01.str.29.5.1020
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS8wMS5zdHIuMjkuNS4xMDIw
imprint Ovid Technologies (Wolters Kluwer Health), 1998
imprint_str_mv Ovid Technologies (Wolters Kluwer Health), 1998
institution DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1
issn 0039-2499, 1524-4628
issn_str_mv 0039-2499, 1524-4628
language English
last_indexed 2024-03-01T18:13:03.233Z
match_str romanic1998matrixmetalloproteinaseexpressionincreasesaftercerebralfocalischemiainratsinhibitionofmatrixmetalloproteinase9reducesinfarctsizeinhibitionofmatrixmetalloproteinase9reducesinfarctsize
mega_collection Ovid Technologies (Wolters Kluwer Health) (CrossRef)
physical 1020-1030
publishDate 1998
publishDateSort 1998
publisher Ovid Technologies (Wolters Kluwer Health)
record_format ai
recordtype ai
series Stroke
source_id 49
spelling Romanic, Anne M. White, Raymond F. Arleth, Anthony J. Ohlstein, Eliot H. Barone, Frank C. 0039-2499 1524-4628 Ovid Technologies (Wolters Kluwer Health) Advanced and Specialized Nursing Cardiology and Cardiovascular Medicine Neurology (clinical) http://dx.doi.org/10.1161/01.str.29.5.1020 <jats:p><jats:italic>Background and Purpose</jats:italic>—Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade the extracellular matrix and are implicated in numerous pathological conditions including atherosclerosis, inflammation, and tumor growth and metastasis. In the brain, the endothelial cell wall, strengthened by tight junctions, defines the blood-brain barrier (BBB). The extracellular matrix molecules constitute the basement membrane underlying the vasculature and play a critical role in maintaining the integrity of the BBB. After focal stroke, there is a breakdown of the BBB with an associated increase in vascular permeability, inflammatory cell influx, and neuronal cell death. The present study was designed to investigate the effects of MMP expression after stroke.</jats:p><jats:p><jats:italic>Methods</jats:italic>—Focal stroke was produced by permanent middle cerebral artery occlusion (MCAO) in the rat, and MMP protein expression was measured by Western blot and zymogram analysis over a time course ranging from 6 hours to 30 days (n=32). Immunohistochemistry at 1 and 5 days (n=8 and 6, respectively) was also utilized to characterize the expression of several MMPs and related proteins after stroke, including their cellular source. To test the hypothesis that early increased MMP-9 expression is involved in ischemic brain injury, a neutralizing monoclonal antibody directed against MMP-9 was administered intravenously (n=7 per group) 1 hour before MCAO, and infarct size was measured 24 hours later.</jats:p><jats:p><jats:italic>Results</jats:italic>—MMP expression increased progressively over time after stroke. After 12 hours, significant (<jats:italic>P</jats:italic>&lt;0.05) MMP-9 activity was observed that reached maximum levels by 24 hours (<jats:italic>P</jats:italic>&lt;0.001), then persisted for 5 days at this level and returned to basal (zero) levels by 15 days. On the basis of morphological criteria, MMP-9 appeared to stain with endothelial cells and neutrophils identified both within and at the periphery of the infarct within 24 hours of focal ischemia. After 5 days, MMP-9 appeared to stain with macrophages present within the infarcted brain. MMP-2 activity was significantly (<jats:italic>P</jats:italic>&lt;0.001) increased by 24 hours and was maximum after 5 days following MCAO. MMP-2 appeared to stain with macrophages present within the infarcted region. Unlike MMP-9 and MMP-2, tissue inhibitor of metalloproteinase-1 was identified at comparable levels in both control and ischemic tissue after MCAO. MMP-1 and MMP-3 could not be detected in the brain after focal stroke. When an MMP-9–neutralizing monoclonal antibody was administered systemically, animals exhibited significantly reduced infarct size (ie, a 30% reduction compared with non–immune antibody controls;<jats:italic>P</jats:italic>&lt;0.05).</jats:p><jats:p><jats:italic>Conclusions</jats:italic>—These results demonstrate that early increased MMP-9 expression in endothelial cells and infiltrating neutrophils is a significant response to cerebral focal ischemia and that selective inhibition of MMP-9 activity can significantly reduce brain injury after stroke.</jats:p> Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size Stroke
spellingShingle Romanic, Anne M., White, Raymond F., Arleth, Anthony J., Ohlstein, Eliot H., Barone, Frank C., Stroke, Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size, Advanced and Specialized Nursing, Cardiology and Cardiovascular Medicine, Neurology (clinical)
title Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_full Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_fullStr Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_full_unstemmed Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_short Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_sort matrix metalloproteinase expression increases after cerebral focal ischemia in rats : inhibition of matrix metalloproteinase-9 reduces infarct size
title_sub Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
title_unstemmed Matrix Metalloproteinase Expression Increases After Cerebral Focal Ischemia in Rats : Inhibition of Matrix Metalloproteinase-9 Reduces Infarct Size
topic Advanced and Specialized Nursing, Cardiology and Cardiovascular Medicine, Neurology (clinical)
url http://dx.doi.org/10.1161/01.str.29.5.1020